Stem Cell Therapy Market Size, Growth, Statistics Report 2028

report image

Stem Cell Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Adult Stem Cell Therapy, Embryonic Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, and Other Stem Cell Therapy), Treatment (Allogeneic and Autologous), Application (Musculoskeletal, Dermatology, Cardiology, Drug Discovery & Development, and Other Applications), and End User (Hospitals & Specialty Clinics and Academic & Research Institutes), and Geography

Publication Month: Feb 2023 | Report Code: TIPHE100000991 | No. of Pages: 206 | Category: Biotechnology | Status: Published

The stem cell therapy market is expected to grow from US$ 2,278.49 million in 2022 to US$ 6,206.89 million by 2028; it is estimated to grow at a CAGR of 18.2% from 2022 to 2028.

Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under a controlled environment in the body or a clinical laboratory, these cells divide to form more cells, called daughter cells. With the advent of modern health science, these cells have been demonstrated to play a major role in understanding the occurrence of diseases, the generation of advanced regenerative medicines, and the discovery of other drugs. Stem cells are formed in embryos, bone marrow, body fats, and umbilical cord blood, among others.

Strategic Insights

Report Coverage - Stem Cell Therapy Market
Report CoverageDetails
Market Size Value inUS$ 2,278.49 million in 2022
Market Size Value byUS$ 6,206.89 million by 2028
Growth rateCAGR of 18.2% from 2022 to 2028
Forecast Period2022-2028
Base Year2022
No. of Pages206
No. of Tables138
No. of Charts & Figures81
Historical data availableYes
Segments coveredType, Treatment, Application, and End User
Free Sample Copy Available

Market Insights

Increasing Organic and Inorganic Strategies by Key Players

The key market players are taking up various organic and inorganic strategies, including mergers and acquisitions, expansions, and new product launches, to stay competitive in the market.

  • In October 2022, Medipost (CEO Won-Il Oh) announced the launch of its Contract Development and Manufacturing Organization (CDMO) business for cell and gene therapy products in Korea. The company announced its new GMP facilities will house 10 cleanrooms and production facilities equipped with up-to-date equipment exclusively for CDMO.
  • In December 2019, Lineage Cell Therapeutics and AgeX Therapeutics, in partnership, registered a US patent for the method of generating induced pluripotent stem cells.
  • In June 2021, Allogene Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALLO-605, the Company’s next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma. The FDA granted Fast Track designation based on the potential of ALLO-605 to address the unmet need for patients who have failed other standard multiple myeloma therapies.

Thus, many organic and inorganic strategies in the stem cell therapy market enable healthcare professionals to provide improved services.

Lucrative Regions in Stem Cell Therapy Market

Lucrative Regions in Stem Cell Therapy Market

Get more information on this report :

Stem cell therapy has been widely investigated across the world. Stem cells are mainly used to replace dying cells and reconstruct damaged tissues. Based on the results of extensive stem cell research conducted so far, many scientists have claimed that these cells could probably be utilized to generate cures and treatments for diseases such as cancer and cardiovascular disease. Newly developed stem cell therapies involve replacing disease-causing cells with stem cells. Many potential treatments involving stem cells are in different phases of clinical trials. The FDA has also approved a few stem cell therapies involved in treating complications related to stem cell transplants. In September 2021, the US Food and Drug Administration (FDA) announced approval for "Ruxolitinib" for treating "graft-versus-host-disease" (GVHD) in patients aged 12 and above. Ruxolitinib provides a patient new hope that suffers from fatal complications associated with stem cell transplants.

Researchers are further investigating the use of stem cell therapy in treating autoimmune disorders. For example, stem cells can turn into the cells of damaged organs and are used in treating autoimmune diseases. Treatment is carried out using mesenchymal stem cells or fetal stem cells. Hematopoietic stem cells are currently used for treating more than 80 medical conditions, including immune system diseases; blood disorders; neurological disorders; metabolic disorders; genetic disorders; and cancer types such as leukemia and lymphoma.

Type Insights

Based on type, the stem cell therapy market is segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and other stem cell therapy. The adult stem cell therapy segment held the largest market share in 2021. However, the induced pluripotent stem cell therapy segment is anticipated to register the highest CAGR during the forecast period (2022–2028).

Treatment Insights

Based on treatment, the global stem cell therapy market is bifurcated into allogeneic and autologous. The allogenic segment held the larger stem cell therapy market share in 2021. Moreover, the autologous segment is expected to grow at the highest CAGR during the forecast period.

Application Insights

In terms of application, the stem cell therapy market is divided into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications. The drug discovery and development segment held the largest market share in 2021, and it is expected to register the highest CAGR during the forecast period.

Stem Cell Therapy Market, by Type – 2021 and 2028

Stem Cell Therapy Market, by Type – 2021 and 2028

Get more information on this report :

End User Insights

Based on end user, the stem cell therapy market is bifurcated into academic & research institutes and hospitals & clinics. The academic & research institutes segment held a larger market share in 2021, and the same segment is expected to register a higher CAGR in the market during the forecast period (2022–2028).

Companies in the stem cell therapy market majorly adopt inorganic strategies such as mergers and acquisitions. A few of the recent key developments in the market are listed below.

  • In June 2021, the USFDA granted Fast Track designation to ALLO-605, the next-generation AlloCAR T therapy offered by Allogene Therapeutics, Inc., targeting BCMA for the treatment of relapsed or refractory multiple myeloma. The designation was granted on the basis of the potential of ALLO-605 to address the unmet needs of patients who didn’t respond to other standard multiple myeloma therapies.
  • In June 2021, MEDIPOST announced that the company has expanded the production facilities for its knee osteoarthritis stem cell products, CARTISTEM and SMUP-IA-01, and will start preparing for GMP (Good Manufacturing Practice) certification.
  • In September 2022, Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics, Inc. and will focus primarily on advancing its CendR Platform technology product candidates in a range of oncology indications, in addition to Caladrius’ existing development programs.
  • In March 2019, BioTime, Inc acquired Asterias Biotherapeutics, Inc. which deals in regenerative medicines to consolidate its stem cell therapies product portfolio.

Company Profiles

  • MEDIPOST
  • Pharmicell Co., Inc.
  • RichSource
  • BioTime, Inc.
  • Mesoblast Limited
  • Holostem Terapie Avanzate Srl
  • U.S. Stem Cell, Inc.
  • Caladrius Biosciences, Inc.
  • TiGenix NV
  • AlloSource

Frequently Asked Questions

Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, generation of advanced regenerative medicines, and drug discovery. There are certain sources such as embryo, bone marrow, body fats, and umbilical cord blood amongst others, where stem cells are generated.
Increasing research activities related to stem cell therapy for effective disease management and growing prevalence of cancer are the most significant factors responsible for the overall market growth.
Based on type segment, the adult stem cell therapy segment took the forefront leaders in the worldwide market by accounting largest share in 2021 and is expected to continue to do so till the forecast period.
Based on the treatment, allogenic segment took the forefront leaders in the worldwide market by accounting largest share in 2021.
Academic & Research institutes segment dominated the global stem cell therapy market and accounted for the largest market share during the forecast period of 2022-2028.
MEDIPOST, RichSource, BioTime, Inc., Mesoblast Limited, Holostem Terapie Avanzate Srl, U.S. Stem Cell, Inc., TiGenix NV, AlloSource, NuVasive Inc, JCR Pharmaceuticals Co. Ltd. and among others are among the leading companies operating in the stem cell therapy market.
Global stem cell therapy market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.

The List of Companies - Stem Cell Therapy Market

  1. MEDIPOST
  2. RichSource
  3. BioTime, Inc.
  4. Mesoblast Limited
  5. Holostem Terapie Avanzate Srl
  6. U.S. Stem Cell, Inc.
  7. TiGenix NV
  8. AlloSource
  9. NuVasive Inc
  10. JCR Pharmaceuticals Co. Ltd.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the stem cell therapy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global stem cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPHE100000991
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market


Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount